New Cures Start With Better Targets

1. To find drugs for diseases where others have failed.
2. To understand mechanistic links between biological clues.
3. To see how cell types differ in behavior and drug response.
4. To unlock value hiding in data.

1. AI prioritized, genetically informed targets and biomarkers.
2. Insights from curated biological interaction and omics data.
3. Patented mechanistic simulation of cellular biology
4. Virtual screening with a curated library of over 10 million ligands.

1. Projects start from a genetic context for human disease (e.g. familial inheritance, differential expression, etc)
2. We create cell-specific models to predict and rank-order adjacent genes most likely to be drivers or points of convergence in disease.
3. The platform predicts druggability and produces output reports with data tables, graphics, and supporting publication references.
4. To validate targets, we simulate patient tissue and quantify the impact of target modulation.
5. For high-confidence targets, we virtually screen for compounds that can bind to the target pocket then bring hit compounds into the lab for in vitro validation.

1. Parkinson's disease small molecules discovered using the NI tools are in development at Vincere Biosciences.
2. Collaboration with Oxford University funded by Michael J Fox Foundation to identify convergences between LRRK2 and GBA.
3. Collaboration with Mayo Clinic funded by Michael J Fox Foundation to identify targets for G2019S LRRK2 Parkinson's

For more information, please contact info@neuroinitiative.com